PATHOGENETIC FEATURES OF PHENOTYPES CLUSTERS OF BRONCHIAL ASTHMA AT THE REHABILITATION STAGE
Practically valuable information on the use of the IMMUNOGLOBULIN SIGARDIS drug as a pathogenetic treatment of patients with a defect in antibody production. The article presents data from the study of the drug for compliance with the criteria, presented to the Intravenous immunoglobulin by the World Health Organization, the comparative characteristics of the antibodies that make up the drug according to the spectra and titers with the Russian, the data on the clinical and laboratory eﬃcacy of the drug.